Traders assign a strong 91.5% implied probability to no new COVID variant of concern before 2027 because global surveillance through mid-2026 shows continued Omicron sublineage evolution without meeting WHO or ECDC criteria for elevated transmissibility, severity, or immune escape that would trigger designation. Recent strains such as BA.3.2, XFG, NB.1.8.1, and PQ.16.1.1 have spread in multiple countries and appear in wastewater data, yet health agencies report no substantial changes in disease outcomes or vaccine performance relative to prior circulating forms. Updated 2026–2027 vaccines target the JN.1 lineage without urgent reformulation needs, and case trends remain consistent with seasonal patterns rather than disruptive waves. With only months remaining until 2027, the absence of rapid escalation or new high-impact mutations supports the current trader consensus on low near-term risk.